Direct oral anticoagulants in prevention and treatment of cancer-associated thrombosis

Patients with malignancy have higher risk of developing cancer-associated thrombosis (CAT), with predominance of venous thromboembolism (VTE). CAT in these patients leads to the delay of specific cancer treatment, worse treatment outcomes and also increased mortality rates. This article is evaluating the role of direct oral anticoagulants (DOAC) in the prophylaxis and treatment of VTE in patients with CAT. The review shed the light on the newest recommendations and guidelines, according to the newest treatment guidelines, but it also discusses the potential risks of DOAC therapy in patients with CAT. Compared to the previous recommendations, in the latest clinical guidelines for the prevention and treatment of CAT, DOAC are becoming more important. However, considering that cancer patients represent a highly specific group of patients, diversification and expansion of CAT anticoagulant therapy provides personalized approach to each patient achieving more efficient and safer profile of anticoagulant therapy.